Question thread · 2 questions
How many people with cystic fibrosis have accessed Orkambi through the Peer Approved Clinical System (PACS) Tier Two Panel that has been in effect since 1 June 2018.
Started with S5W-19151 on 2 Oct 2018; latest 25 Oct 2018. Each later question says it follows up an earlier answer.
Follow-ups
1
Span
23 days
Answered
2 of 2
Asked by
2
The thread, in order
Each answer’s opening lines; open a question for the full text-
To ask the Scottish Government how many people with cystic fibrosis have accessed Orkambi through the Peer Approved Clinical System (PACS) Tier Two Panel that has been in effect since 1 June 2018.
Jeane Freeman, 4 Oct 2018: I refer the member to the answer to question S5W-18944 on ? 27 September 2018. All answers to written parliamentary questions are available on the Parliament’s website, the search facility for which can be found at: http://www.parliament.scot/parliamentarybusiness/28877.aspx -
Further to the answers to questions S5W-18944 and S5W-19151 by Jeane Freeman on 27 September and 4 October 2018 respectively, how many people have accessed the cystic fibrosis drug, Orkambi, through the Peer Approved Clinical System (PACS) Tier Two Panel.
Jeane Freeman, 2 Nov 2018: There were six requests for Orkambi through the Peer Approved Clinical System (PACS) Tier Two process between 1 June 2018 and 31 September 2018. Four of these were accepted and two decisions were deferred by the relevant Health Boards for further consideration.
How this thread is put together
- Follow-up
- A question whose text says it is “further to the answer to question …” (or reply, response, or asks for a “substantive answer” to an earlier question). The question it names is its parent.
- Several citations
- When a question cites more than one earlier question, the most recent one we hold is used as the parent; the others are listed as “also cites”.
- Thread
- Follow parents back to the first question; every question that leads back to it is in this thread. Branches are shown in date order.